Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics announced on September 8 that partner Novartis has dosed the first patient in a Phase 2 trial of the VAV1-targeted drug MRT-6160, also known as DDY391, in people with Sjögren's disease, triggering a $50 million milestone payment to Monte Rosa and marking the first step in a collaboration that could eventually be worth up to $2.1 billion. Novartis is footing the entire bill for the study, which will track participants for as long as a year of treatment and compare the drug against placebo across multiple sites to select the right dose before a Phase 3 program begins, and Monte Rosa stands to collect further payments each time a new Phase 2 study opens for MRT-6160 in other immune conditions. In an earlier Phase 1 trial, the molecule knocked down VAV1 protein levels by over 90% in patients' T cells and calmed key markers of inflammation without triggering any serious side effects. Monte Rosa also reported on August 6 that enrollment and dosing had wrapped up in its GFORCE-1 study of MRT-8102 in people with elevated cardiovascular risk, with results due later in 2026, and that its MODeFIRe-1 study pairing MRT-2359 with the prostate cancer drug apalutamide is up and running, backed by $626 million in cash, equivalents, and marketable securities as of June 30 that management says can fund operations into 2029. The progress has come at a cost: collaboration revenue fell to $9.0 million in the second quarter of 2026 from $23.2 million a year earlier, research spending rose to $48.0 million from $30.7 million, administrative costs climbed to $10.1 million from $8.1 million, and the quarterly net loss ballooned to $43.4 million, more than triple the $12.3 million loss in the same period of 2025. Hedge fund ownership edged up to 36 funds from 35, while 21.52% of the float is sold short, an unusual pairing that suggests the market has not settled on whether the milestone cash flow outweighs the widening losses.

Monte Rosa Therapeutics announced second-quarter 2026 financial results and clinical progress, reporting a cash position of $626.0 million expected to fund operations into 2029. The company completed enrollment and dosing in the GFORCE-1 Phase 1 study of MRT-8102 in subjects with elevated cardiovascular disease risk, with data readout anticipated in the second half of 2026. Monte Rosa plans to initiate multiple Phase 2 studies for MRT-8102, including a Phase 2b trial in patients with elevated atherosclerotic risk and cardiometabolic syndrome in the second half of 2026, a study in gout patients in the fourth quarter of 2026 or first quarter of 2027, and a study in moderate to severe hidradenitis suppurativa in the first half of 2027. Collaborator Novartis activated a Phase 2a/b trial of the VAV1-directed molecular glue degrader MRT-6160 in Sjögren's disease, triggering an expected milestone payment to Monte Rosa under a deal worth up to $2.1 billion in milestones. The company also activated the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide for metastatic castration-resistant prostate cancer patients with androgen receptor mutations. Net loss for the quarter was $43.4 million, compared to $12.3 million in the prior-year period, while collaboration revenue fell to $9.0 million from $23.2 million.

A new competitive landscape report from DelveInsight reveals that more than 80 active pharmaceutical companies are developing over 90 pipeline molecular glues, with approximately 7 therapies in late-stage development and 15 in mid- or early-stage trials. Key players include Revolution Medicines, Gluetacs Therapeutics, Captor Therapeutics, Nurix Therapeutics, Monte Rosa Therapeutics, and Neomorph, among others, evaluating candidates such as Daraxonrasib, GT919, CT-01, and NEO-811. The report highlights notable mechanisms of action including RAS(ON) inhibition, GSPT1 degradation, and c-Myc degradation, and covers recent milestones like the FDA’s Breakthrough Therapy Designation for Daraxonrasib and the first patient dosing in Degron Therapeutics’ Phase 1 trial of DEG6498. Approved molecular glues POMALYST and REVLIMID from Bristol Myers Squibb are also profiled, underscoring the class’s established role in multiple myeloma and other hematologic malignancies.